A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma

Étude multicentrique de phase 3, randomisée, en ouvert, visant à comparer l'efficacité et la sécurité de bb2121 aux trithérapies standard chez les sujets atteints de myélome multiple récidivant ou réfractaire (MMRR) (KarMMa-3).

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

MAGNETISMM-3, an open-label, multicenter, non-randomized phase 2 study of ELRANATAMAB (PF-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma